Health & Fitness
Health and Fitness
Health and Fitness
Wed, July 28, 2010
Tue, July 27, 2010 Stryker, Zimmer Holdings, Smith & Nephew, CONMED and Johnson & Johnson
CHICAGO--([ BUSINESS WIRE ])--Zacks.com Analyst Blog features: Stryker Corp. (NYSE: [ SYK ]), Zimmer Holdings (NYSE: [ ZMH ]), Smith & Nephew (NYSE: [ SNN ]), CONMED Corp (Nasdaq: [ CNMD ]) and Johnson & Johnson (NYSE: [ JNJ ]).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=4579 ]
Here are highlights from Mondaya™s Analyst Blog:
Earnings Scorecard: Stryker
Medical devices giant Stryker Corp. (NYSE: [ SYK ]) produced a mixed bag in the second quarter, matching earnings expectations while missing on the revenue front. Earnings of 80 cents per share came in line with the Zacks Consensus Estimate and net income leapt 9.5% year-over-year, led by healthy growth at the MedSurg Equipment division.
Revenues grew 7.6% year-over-year to $1,758 million, but trailed the Zacks Consensus Estimate of $1,767 million as higher sales from MedSurg were marred by a sluggish Orthopedic business. International revenue growth was muted by lower Orthopedic Implants shipments, discontinued product lines, termination of distributor contracts. Lower-than-expected sales hit Strykera™s shares which slipped $1.79 (or 3.49%) in after-market trading on July 20.
Agreement of Analysts
The overall trend in estimate revisions for fiscal 2010 is inclined towards the negative side following the second quarter results. Out of 27 analysts covering the stock, 10 have chopped their estimates over the past week while 5 have made positive revisions. Likewise, 11 analysts (out of 28) have trimmed their forecasts for fiscal 2011 over the same period, with 4 raising their estimates. A similar trend is observed for annual estimates over the past month.
The bearish sentiment has been fueled by the lower-than-expected Orthopedic results in the second quarter, attributable to deceleration across the board as evidenced by weak hips, knees and spinal devices sales. Moreover, product pricing pressure on Strykera™s implant products, which mirrors a general trend in the industry, also contributed to the gloomy opinion. Conversely, sustained double-digit growth at MedSurg coupled with improving margin trends is a factor which inspires bullishness in some analysts.
The downswing in estimate revisions, which indicates weak performances moving forward, not only exert a meaningful impact on the Zacks Rank but also reflect the potential for significant downward pressure on the stock.
Magnitude of Estimate Revisions
Downward estimate revisions accompanied by a directional agreement have led to a decline in annual forecasts for Stryker. Estimates for fiscal 2010 and 2011 have gone down by a penny over the past week. The current Zacks Consensus Estimate for fiscal 2010 is $3.26, reflecting a 10.62% year-over-year growth.
Remaining Neutral on Stryker
Stryker is one of the worlda™s largest medical devices companies operating in the global orthopedic space. The companya™s well diversified product portfolio is a natural hedge against the risk of revenue shortfall in a volatile economy.
Stryker continues to expand its product range by acquiring complementary products or businesses. As a part of this initiative, the company acquired medical devices maker Ascent Healthcare in fourth-quarter 2009, providing a major boost to its MedSurg Equipment segment.
However, the Orthopedic industry is highly competitive and Stryker faces stiff challenges from it peers such as Zimmer Holdings (NYSE: [ ZMH ]), Smith & Nephew (NYSE: [ SNN ]), CONMED Corp (Nasdaq: [ CNMD ]), Biomet and DePuy, a division of Johnson & Johnson (NYSE: [ JNJ ]). Strykera™s spinal implants products, in particular, are facing the heat in a market where rival offerings continue to make in-roads, hurting the companya™s market share. The spinal business is expected to remain challenged for the remainder of fiscal 2010.
Moving forward, we feel that Stryker should benefit from the resurgent replacement hips and knees markets, which have rebounded from a slowdown in the height of the recession. Also, new product launches and acquisitions should catalyze growth across Orthopedic and MedSurg divisions.
While acknowledging the strength at MedSurg, we point out some areas of concerns such as pricing pressure and stiff competition in the orthopedic space, sluggish European markets, and a challenging hospital capital spending environment, which could potentially dent future earnings. As such, we remain in the Neutral territory, which is supported by the short-term Zacks #3 Rank (Hold).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=5514 ].
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: [ http://at.zacks.com/?id=5516 ]
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=4580 ].
Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.
Follow us on Twitter: [ http://twitter.com/zacksresearch ]
Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ]
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
